Genomic and Epidemiologic Surveillance of SARS-CoV-2 in the Pandemic Period: Sequencing Network of the Lazio Region, Italy.

Next Generation Sequencing SARS-CoV-2 SARS-CoV-2 variants epidemiology genomic surveillance sequencing network

Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
31 Oct 2023
Historique:
received: 31 08 2023
revised: 24 10 2023
accepted: 27 10 2023
medline: 27 11 2023
pubmed: 25 11 2023
entrez: 25 11 2023
Statut: epublish

Résumé

Since the beginning of the COVID-19 pandemic, large-scale genomic sequencing has immediately pointed out that SARS-CoV-2 has rapidly mutated during the course of the pandemic, resulting in the emergence of variants with a public health impact. In this context, strictly monitoring the circulating strains via NGS has proven to be crucial for the early identification of new emerging variants and the study of the genomic evolution and transmission of SARS-CoV-2. Following national and international guidelines, the Lazio region has created a sequencing laboratory network (WGSnet-Lazio) that works in synergy with the reference center for epidemiological surveillance (SERESMI) to monitor the circulation of SARS-CoV-2. Sequencing was carried out with the aims of characterizing outbreak transmission dynamics, performing the genomic analysis of viruses infecting specific categories of patients (i.e., immune-depressed, travelers, and people with severe symptoms) and randomly monitoring variant circulation. Here we report data emerging from sequencing activities carried out by WGSnet-Lazio (from February 2020 to October 2022) linked with epidemiological data to correlate the circulation of variants with the clinical and demographic characteristics of patients. The model of the sequencing network developed in the Lazio region proved to be a useful tool for SARS-CoV-2 surveillance and to support public health measures for epidemic containment.

Identifiants

pubmed: 38005872
pii: v15112192
doi: 10.3390/v15112192
pmc: PMC10674723
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministero della Salute
ID : 5M-2020-23682104
Organisme : Ministero della Salute
ID : Ricerca Corrente - Linea 1

Références

Genomics Inform. 2020 Dec;18(4):e44
pubmed: 33412760
Cell. 2022 Jul 7;185(14):2422-2433.e13
pubmed: 35772405
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
BMC Genomics. 2016 Sep 05;17:708
pubmed: 27595578
Sci Rep. 2022 Apr 19;12(1):6457
pubmed: 35440671
Lancet. 2022 Apr 23;399(10335):1618-1624
pubmed: 35397851
JMIR Bioinform Biotech. 2022 Mar 14;3(1):e31536
pubmed: 35309411
Biomed Pharmacother. 2022 Oct;154:113522
pubmed: 36030585
J Med Virol. 2021 Sep;93(9):5638-5643
pubmed: 33951211
PLoS One. 2023 Apr 27;18(4):e0282806
pubmed: 37104488
J Med Virol. 2022 Jul;94(7):2969-2976
pubmed: 35246846
Virus Res. 2022 Jul 2;315:198765
pubmed: 35367284
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
Virology. 2022 Jul;572:44-54
pubmed: 35580380
Epidemiol Infect. 2021 Apr 30;149:e110
pubmed: 33928885
Infect Genet Evol. 2023 Mar;108:105405
pubmed: 36681102
Nature. 2022 Jun;606(7916):848-849
pubmed: 35750920
J Med Virol. 2022 Jan;94(1):310-317
pubmed: 34506640
Nat Microbiol. 2021 Jul;6(7):821-823
pubmed: 34108654
Int J Infect Dis. 2021 Feb;103:282-287
pubmed: 33259879
Cell Rep. 2022 May 17;39(7):110829
pubmed: 35550680
Viruses. 2022 Nov 12;14(11):
pubmed: 36423117
World J Clin Cases. 2022 Jan 7;10(1):1-11
pubmed: 35071500
Nature. 2022 Feb;602(7896):300-306
pubmed: 34823256
Emerg Microbes Infect. 2022 Dec;11(1):337-343
pubmed: 34935594
Rev Med Virol. 2022 Sep;32(5):e2381
pubmed: 35856385

Auteurs

Martina Rueca (M)

National Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.

Giulia Berno (G)

National Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.

Alessandro Agresta (A)

National Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.

Martina Spaziante (M)

National Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.

Cesare Ernesto Maria Gruber (CEM)

National Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.

Lavinia Fabeni (L)

National Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.

Emanuela Giombini (E)

National Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.

Ornella Butera (O)

National Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.

Alessandra Barca (A)

Direzione Regionale Salute E Integrazione Sociosanitaria, Area Promozione Della Salute E Prevenzione-Regione Lazio, 00145 Rome, Italy.

Paola Scognamiglio (P)

National Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.
Direzione Regionale Salute E Integrazione Sociosanitaria, Area Promozione Della Salute E Prevenzione-Regione Lazio, 00145 Rome, Italy.

Enrico Girardi (E)

National Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.

Fabrizio Maggi (F)

National Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.

Maria Beatrice Valli (MB)

National Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.

Francesco Vairo (F)

National Institute for Infectious Diseases 'Lazzaro Spallanzani', IRCCS, 00149 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH